Federal Circuit Finds That FDA Citizen Petition Could Give Rise to Antitrust Liability

by Foley & Lardner LLP
Contact

In Tyco Healthcare Group LP v. Mutual Pharmaceutical Co., Inc., the Federal Circuit remanded-in-part for the district court to determine whether Tyco’s citizen petition to the FDA gave rise to antitrust liability. Judge Newman wrote a dissenting opinion warning against the chilling effect that antitrust liability could have on a citizen’s right to communicate with the FDA on matters relating to drug safety and efficacy.

Mutual’s ANDA And Tyco’s Citizen Petition

The case centered on Tyco’s temazepam product, which it markets under the brand name Restoril, and Mutual’s Abbreviated New Drug Application (ANDA) seeking FDA approval to market a generic version of Restoril. According to the Federal Circuit decision, the Tyco patents listed in the Orange Book all recite “7.5 mg formulations of temazepam having a specific surface area between 0.65 and 1.1 square meters per gram (m2/g).” In its ANDA, Mutual sought approval of a temazepam product having “a specific surface area of not less than 2.2 m2/g,” e.g., outside of the range recited in the Tyco patents.

In the ensuing ANDA litigation, the district court granted judgment of non-infringement based on Mutual’s ANDA, but the litigation continued on the issue of invalidity. The day after the non-infringement judgment, Tyco filed a citizen petition with the FDA that “urged the FDA to change the criteria for evaluating the bioequivalence of proposed generic temazepam products in order to ‘help ensure therapeutic equivalence’ of generic temazepam to Restoril.”

In particular, Tyco alleged that ”the safety and efficacy of Restoril was likely linked to its pharmacokinetic profile, and that changes to parameters such as specific surface area in a generic version could alter that profile and thereby affect the safety and efficacy of the generic version as compared to Restoril.” Thus, Tyco urged the FDA to adopt proposed guidelines that “would require generic temazepam manufacturers to demonstrate bioequivalence to Restoril through a series of pharmacokinetic parameters considerably more extensive and complex than the parameters traditionally required by the FDA for a bioequivalence determination.”

Barely one month later, while Tyco’s citizen petition was still pending, the FDA approved Mutual’s ANDA.

A few months later, FDA denied Tyco’s citizen petition.

In the ongoing district court litigation, Mutual alleged that Tyco’s citizen petition was a “sham” that constituted an antitrust violation. The district court rejected that line of argument, and ruled for Tyco on all of Mutual’s antitrust counterclaims.

The Federal Circuit Decision

The Federal Circuit opinion was authored by Judge Bryson and joined by Judge Moore. Judge Newman filed a dissenting opinion.

Judge Bryson explained the antitrust liability for “sham” litigation as follows:

A party is ordinarily exempt from antitrust liability for bringing a lawsuit against a competitor. That principle is known as “Noerr-Pennington immunity,” because it originated with the Supreme Court’s decisions in Eastern Railroad Presidents Conference v. Noerr Motor Freight, Inc., 365 U.S. 127 (1961), and United Mine Workers of Am. v. Pennington, 381 U.S. 657 (1965). There is a recognized exception to Noerr-Pennington immunity for “sham litigation,” which the Supreme Court has defined as litigation that (1) is “objectively baseless in the sense that no reasonable litigant could realistically expect success on the merits” (the objective element), and (2) is motivated by a desire “to interfere directly with the business relationships of a competitor” (the subjective element). Prof’l Real Estate Investors, Inc. v. Columbia Pictures Indus., Inc., 508 U.S. 49, 60-61 (1993) (“PRE”).

The district court had rejected the sham litigation claim related to the citizen petition on the ground that the entire doctrine applies only to litigation, but the Federal Circuit majority noted that the doctrine has been applied to administrative petitions, including citizen petitions. Thus, the Federal Circuit considered the claim under the two-part PRE test.

With regard to part (1), the Federal Circuit majority found that the FDA decision denying the petition raised a question as to whether it was “objectively baseless”:

Particularly probative of whether the citizen petition was reasonable is the FDA’s response, which denied the petition in terms indicating that, in the FDA’s view, it was wholly without merit. The FDA found that Tyco had “provided no evidence from clinical trials, pharmacokinetic studies, bioequivalence testing, or any other source . . . . Instead the petition relies entirely on uncorroborated generalities and theoretical speculation to support its critical point.” The FDA also concluded that the petition “fail[ed] to provide any evidence at all about the existence, extent, or significance of surface area variations for any other generic temazepam products at any dosage strength.”

With regard to part (2), the Federal Circuit majority found that the timing of the citizen petition (filed one week before the expiration of the 30 month stay of approval of Mutual’s ANDA) and an internal email between Tyco’s research and development department and its vice president of intellectual property that the majority found could support a finding that “Tyco knew the theory in its citizen petition lacked merit” constituted “sufficient evidence from which a reasonable finder of fact could determine that Mutual had satisfied the subjective element necessary to show that Tyco’s citizen petition was a sham.”

Thus, the Federal Circuit majority found that the district court should not have granted summary judgment against Mutual on the citizen petition issue. However, the Federal Circuit questioned whether Mutual had proven any antitrust injury from the citizen petition. Thus, the Federal Circuit indicated that the district court “should determine whether Mutual suffered an anticompetitive harm in the form of a delay in the approval of its ANDA due to the filing of Tyco’s citizen petition with the FDA.” If not, Tyco would be entitled to summary judgment.

Judge Newman’s Dissent

Judge Newman disagreed that a citizen petition can give rise to antitrust liability:

No antitrust law was violated by Tyco’s communication to the FDA. The FDA is charged with establishing and securing drug safety and efficacy, for a new drug and for its generic counterparts. There can be no doubt as to a citizen’s right to communicate with the government on matters of concern.…. Such right is not eliminated when the petitioner is in a competitive relationship.

Citizen Petition: Strategy Or Public Service?

Innovator drug companies may use citizen petitions to encourage the FDA to make it more difficult for competitors to enter the market, but they also may use citizen petitions to raise important safety and efficacy concerns. Innovator drug companies often are in the best position to recognize and understand the risks associated with the drug at issue and proposed generic versions (which, as this case illustrates, are not necessarily identical to the approved brand product). While innovator companies may not always be acting altruistically, their voices in these matters could be important to public health. If the FDA is able to review citizen petitions promptly (as it did here), do we really want every denial to carry a risk of antitrust litigation?

View This Blog

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley & Lardner LLP | Attorney Advertising

Written by:

Foley & Lardner LLP
Contact
more
less

Foley & Lardner LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.